Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways

Kenneth C. H. Fearon, David J. Glass, Denis C. Guttridge

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

Cancer cachexia is characterized by a significant reduction in body weight resulting predominantly from loss of adipose tissue and skeletal muscle. Cachexia causes reduced cancer treatment tolerance and reduced quality and length of life, and remains an unmet medical need. Therapeutic progress has been impeded, in part, by the marked heterogeneity of mediators, signaling, and metabolic pathways both within and between model systems and the clinical syndrome. Recent progress in understanding conserved, molecular mechanisms of skeletal muscle atrophy/hypertrophy has provided a downstream platform for circumventing the variations and redundancy in upstream mediators and may ultimately translate into new targeted therapies.

Original languageEnglish
Pages (from-to)153-166
Number of pages14
JournalCell Metabolism
Issue number2
Publication statusPublished - 8 Aug 2012


Dive into the research topics of 'Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways'. Together they form a unique fingerprint.

Cite this